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Recent epidemiological data have shown a significant decline in breast cancer mortality 
over the past 15 years, as a result of screening programs, better education, and the 
introduction of more effective adjuvant treatments1. However, about 20-30% of the 
patients eventually relapse while approximately 5-7% of cases present with metastatic 
disease at diagnosis2. Metastatic breast cancer is still largely incurable: the median 
survival time is generally in the range of 2 to 4 years3.  
In the metastatic setting, treatment goals can be quite different depending on patient and 
tumor characteristics. There are patients for whom the main objective is symptom 
control to improve or maintain quality of life, cases with life-threatening disease for 
whom a rapid tumor shrinkage is required, asymptomatic patients with slowly growing 
disease for whom a prolonged progression-free survival (PFS) duration is the desirable 
target; finally, some patients can obtain an important survival prolongation and a few of 
them might be cured4. The selection of treatment depends on several factors, including 
patient characteristics, aggressiveness of the disease, response to previous therapies, 
time since last exposure, agents used in the past and cumulative doses. Availability and 
regulatory approval of various anticancer agents further diversify treatment patterns in 
different part of the world.  
A rapidly growing pool of effective treatment options for advanced breast cancer has 
increased response rates and outcome. First, many new cytotoxic drugs are in 
development or  have recently been approved in this setting, such as ixabepilone, 
eribulin and nab-paclitaxel. For instance, in the phase III trial EMBRACE, eribulin 
mesylate improved overall survival (median 13.1 months, 95% CI 11.8-14.3), compared 
to treatment of physician’s choice (median 10.6 months, CI 9.3-12.5; HR 0.81 95% CI 
0.66-0.99, p=0.041), in patient who had received two to five prior chemotherapy 
regimens, including an anthracycline and a taxane for advanced breast cancer.5 In 
clinical studies, 3-weekly nab-paclitaxel has been shown to increase both the safety and 
the efficacy of 3-weekly paclitaxel in patients with advanced breast cancer (median time 
to progression 23 vs 16.9 weeks, hazard ratio 0.75, p=0.006).6 Weekly nab-paclitaxel 
produced meaningful results even in taxanes pre-treated patients (ORR 14% and 16% in 
the 100 and 125 mg/sqm cohorts, respectively; median PFS of 3 and 3.5 months, 
respectively).7  At the same time, research efforts are directed to implement the pool of 
targeted therapies, in order to offer more individualized options to breast cancer patients. 
In fact, the molecular breast cancer subtype is a fundamental determinant of treatment 
choice both in early and advanced setting. Breast cancer consists of at least three 
different diseases: hormone-sensitive breast cancer, the human epidermal growth factor 
receptor (HER2)-positive subtype, and triple-negative disease. Each molecular subtype 
has distinct biological features and a distinct clinical course: hormone receptor–positive 
(HR+) disease is generally characterized by a more indolent course, with a long disease-
free interval (DFI) and a tendency to relapse in the bone or soft tissues; amplification of 
the HER-2 gene confers a more aggressive clinical behavior to the HR+ subgroup, with 
a higher propensity for visceral relapses. Both triple-negative breast cancer and hormone 
receptor–negative (HR-)/HER-2+ breast cancer are aggressive subtypes, with early 
visceral or central nervous system metastases.  
Each molecular subtype requires distinct therapeutic approaches.  
In HR+ tumors, endocrine manipulation is the cornerstone of therapy. Treatment choice 
depends on many factors such as menopausal status and disease-free interval. For 
postmenopausal women many agents are available: non-steroidal and steroidal 
aromatase inhibitors (AI), tamoxifen and fulvestrant; however no definitive 
recommendation for the optimal cascade can be given. For premenopausal patients, the 
data on aromatase inhibitors or fulvestrant are more scanty8. In case of life-threatening 
and rapidly-growing disease, or in case of failure of various endocrine agents, 
chemotherapy has to be considered. Yet, recent studies have shown that HR+ positive 
tumors do also derive benefit from additional targeted agents: data from the BOLERO-2 
trial showed an impressive improvement in progression free-survival with the addition 
of everolimus to exemestane vs exemestane alone as first- or second-line treatment for 
HR+ advanced breast cancer patients, after failure of a non-steroidal AI in the adjuvant 
or metastatic setting (median PFS 10.6 vs 4.1 months according to central assessment, 
HR 0.36;95% CI 0.27-0.47, p<0.001)9. Thus, overcoming endocrine resistance by 
combined targeting of redundancy pathways will be one of the key issues in the near 
future. In this context, even the association of trastuzumab or lapatinib to endocrine 
agents is an important option for HR+/HER2+ patients. Targeting HER2 in HR+ breast 
cancer has been explored as a means of improving endocrine responsiveness. The 
randomized phase II TAnDEM trial included 207 patients with known ER+/HER2+ 
metastatic breast cancer and reported a doubling of progression-free survival with the 
addition of trastuzumab over anastrozole alone (hazard ratio 0.63; 95% CI, 0.47 to 0.84; 
median PFS, 4.8 v 2.4 months; p =0016)10. Finally, results from a phase III trial of 1,286 
patients with metastatic ER+ breast cancer who were randomized to receive either 
letrozole alone or letrozole combined with lapatinib have been published. In patients 
with known ER+/HER2+ tumors (n=219), the addition of lapatinib to letrozole 
significantly reduced the risk of progression as compared to letrozole alone: median PFS 
was 8.2 v 3.0 months, respectively (HR 0.71; 95% CI, 0.53 to 0.96; p=0.019)11. 
In HR-/HER2+ tumors, the incorporation of trastuzumab has substantially reversed the 
negative prognostic impact of HER-2 overexpression/amplification12. However, due to 
the approval of trastuzumab as standard adjuvant therapy for early HER2+ breast cancer 
and the emergency of resistance to this drug, the need of new anti-HER2 agents has 
emerged, as well as the need to clarify the role of continuing trastuzumab beyond 
progression, with different cytotoxic agents. Lapatinib, combined with capecitabine, has 
been approved for the treatment of HER2+ metastatic breast cancer patients, previously 
treated with trastuzumab. Many other anti-HER2 agents are being developed such as T-
DM1, neratinib and pertuzumab. In T-DM1 trastuzumab is conjugated with an 
antimicrotubule drug maytansinoid. Activation of cytotoxicity of this conjugate requires 
internalization into the cell after binding to HER2. A single-arm, phase II trial (n = 112 
MBC patients whose disease progressed on trastuzumab) showed at a follow-up of ≥12 
months a median PFS of 4.6 months (95% CI, 3.9 to 8.6) and an overall response rate of 
26%. Hypokalemia, thrombocytopenia, and fatigue were the most common observed 
adverse events. No dose-limiting cardiotoxicity was reported13. T-DM1 is undergoing 
further testing in the context of several other studies. An open-label, phase III 
randomized trial (EMILIA) is comparing single-agent T-DM1 with the combination of 
capecitabine and lapatinib in patients whose HER2-positive disease has progressed on 
trastuzumab. In another phase III trial MARIANNE, T-DM1 monotherapy is being 
compared to trastuzumab plus a taxane. Neratinib/HKI-272 is an oral, irreversible, small 
molecule inhibitor of EGFR/HER1, HER2, and HER4. In an open-label, phase II study, 
patients with advanced HER2-positive BC with and without prior trastuzumab treatment 
received neratinib. The 16-week PFS was 59% for patients with prior trastuzumab (n = 
63) and 78% for those without (n = 64); median PFS were 22.3 and 39.6 weeks, 
respectively. The most frequent AEs were diarrhea, nausea, vomiting, and fatigue. Grade 
3 or 4 diarrhea occurred in 30% of patients with prior trastuzumab therapy, leading to 
neratinib dose reduction in 29% of this cohort14. A phase III randomized study of 
paclitaxel with either neratinib or trastuzumab in MBC is ongoing, as is a randomized 
phase II study of neratinib alone versus the combination of capecitabine and lapatinib. 
Pertuzumab is a first-in-class recombinant, humanized monoclonal antibody that binds 
to domain II of the HER2 receptor, thus inhibiting HER2 heterodimerization with 
HER1, HER3, and HER4. Recent data from a randomized phase III trial showed that the 
combination of trastuzumab, pertuzumab and docetaxel as first-line treatment for 
HER2+ advanced breast cancer patients, significantly improves progression-free 
survival, with a gain of 6 months in median progression-free survival, as compared to 
the combination of trastuzumab and docetaxel (PFS 18.5 vs 12.4 months, HR 0.62; 95% 
CI, 0.51 to 0.75; P<0.001)15. These results contribute to increase the interest in dual 
HER2 blockade that derived from early breast cancer trials. In this context, the 
combination of trastuzumab and lapatinib in trastuzumab-pretreated patients resulted in 
a more prolonged PFS as compared to lapatinib alone (HR 0.73; 95%CI 0.57-0.93, 
p=0.008)16. 
Lastly, chemotherapy is the only available option so far for the triple-negative (TNBC)  
subtype, which is characterized by the absence of hormone receptors and HER-2 
negativity. At this time, there are no targeted agents that are specifically approved for 
the treatment of this breast cancer subtype. Bevacizumab appears to prolong 
progression-free survival when added to chemotherapy for patients with TNBC (as it 
does for those with HR+/HER2- disease), but does not enhance survival17. Moreover, 
neoadjuvant trials provide conflicting results on the role of bevacizumab for TNBC18,19. 
Although there was great enthusiasm based on phase II data for the combination of 
carboplatin, gemcitabine and the PARP-inhibitor iniparib, the phase III results did not 
support the preliminary data20. A variety of other targeted therapies, including the PI3K 
inhibitors and a number of agents that inhibit DNA repair are under active investigation. 
Nowadays, more patients are likely to be diagnosed with oligo-metastatic disease, 
asymptomatic and in good performance status, due to the use of more sophisticated 
imaging techniques and the information derived from serum-markers dosage; therefore 
more selective therapeutic strategies that include a multimodality approach and local 
therapies are becoming more and more important. A substantial improvement in 
multimodality treatments, including, but not limited to, stereotactic radiosurgery, 
percutaneous radiofrequency ablation, and minimally invasive surgery, has increased the 
chance for disease control in selected patients with limited and indolent metastatic 
disease. In this context, surgery on primary tumor in case of oligometastatic disease has 
been suggested to improve survival, but further data are needed and a randomized trial 
addressing this issue is ongoing. 
Furthermore, an interesting field of research is the molecular characterization of 
metastatic disease. Biopsies of recurrent sites are not routinely performed and treatment 
decision for metastatic disease is mainly based on the receptor status of the primary 
tumor. However, discordance rates in HR and/or HER2 status between primary and 
recurrent tumors have been reported in the range of 10% to 35%21. Reasons for 
discordance may include: test artifacts, tumor heterogeneity, genetic drift during 
progression, selective pressure of adjuvant therapies. Nevertheless, recent reports 
suggest that the change in the receptor status during tumor progression may have also a 
prognostic impact22.  
It is therefore critical to incorporate all disease and patient information to assure the best 
treatment strategy for a given patient. The choice of the best treatment for metastatic 
disease has become even more difficult because the more efficacious agents have been 
progressively incorporated into the management of earlier stages. As a consequence, 
even if the number of patients who experience disease recurrence is gradually 
decreasing, treatment options for recurring patients are more and more influenced by 
prior exposure to adjuvant therapy. Unfortunately, most trials conducted in advanced 
breast cancer do not take into account all these factors that are necessary for an 
appropriate decision-making process.  
A deeper insight into tumor biology and mechanisms of resistance to established 
therapies will allow to develop new cytotoxic or targeted drugs or new combinations of 
available drugs for the treatment of metastatic disease. Key preclinical studies are 
needed, in order to guide the choice of which combination or single-agent deserve to be 
tested in early phase clinical trials. Moreover, well-designed trials that take into account 
the critical issues that frequently present in clinical routine are needed, in order to allow 
for a better translation of scientific results into daily practice.  
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